NM-2-AI

N-Methyl-2-aminoindane (NM-2-AI) is a synthetic stimulant in the aminoindane family. It is the N-methyl derivative of 2-aminoindane and has appeared as a research chemical and in forensic samples. Although it is structurally related to amphetamine and to the entactogen MDAI, its pharmacology is not well established. Animal studies suggest atypical stimulant and mild hallucinogen-like effects, while forensic surveillance has confirmed its presence in biological samples.

Chemistry and history

NM-2-AI contains an indane ring with an amino group at the 2-position and a methyl substituent on the nitrogen. The ring-constrained structure distinguishes it from open-chain amphetamines. It should also be distinguished from MDAI, which contains a methylenedioxy group fused to the aromatic ring.

The US Drug Enforcement Administration reported NM-2-AI in six urine samples submitted to its NPS surveillance programme in 2021. Methamphetamine was also detected in those six samples. The DEA had previously recorded six forensic exhibits between 2014 and 2017 and described a 2015 overdose-death sample in which NM-2-AI was detected alongside a synthetic cannabinoid (DEA alert regarding NM-2-AI, 2021).

Pharmacology

Direct pharmacological information remains limited. A 2023 study examined NM-2-AI in mice and reported changes in sensory processing, body temperature, nociception, grip strength and sensorimotor performance. The researchers also observed a mild hallucinogen-like signal in a startle/prepulse-inhibition test. The main active metabolite identified in the mouse pharmacokinetic study was 2-aminoindane (Behavioral and pharmacokinetic studies of NM-2-AI in mice, 2023).

A 2021 DEA alert noted that earlier aminoindane research had identified some N-methylated derivatives as selective serotonin-releasing agents. However, the alert also stated that the available animal data for NM-2-AI itself did not show dopaminergic effects. These findings should not be conflated with the better-known pharmacology of MDAI or 5-IAI.

Reported effects

Human descriptions of NM-2-AI are sparse. The literature offers no detailed, reliable account of its subjective effects. Its relationship to aminoindanes and amphetamine-like compounds makes stimulant effects plausible, but reports about MDAI or 2-AI cannot be assumed to describe NM-2-AI without direct evidence.

Toxicology and research limitations

The DEA’s 2021 alert confirms that NM-2-AI has appeared in toxicology samples, including one overdose-death investigation in which a synthetic cannabinoid was also detected. That case does not establish NM-2-AI as the cause of death. The report emphasised that pharmacological data were limited.

A 2026 study proposed a first computational toxicity assessment of NM-2-AI and 2-AI. Its predictions are model-based and should not be described as confirmed clinical or animal toxicity findings (Jurowski and Frydrych, 2026). Human pharmacokinetics, acute toxic range, dependence potential and long-term effects remain uncertain.

Related compounds

NM-2-AI is related to 2-AI, MDAI and other substituted aminoindanes. It is the N-methyl derivative of 2-aminoindane, but its pharmacological profile should be considered separately from those compounds.